Skip to main content

SB 1795 — Missouri

Creates provisions relating to biomarker testing

Introduced 2026 session Senate

This page lists STATE bills only. Open States, our source for this data, tracks state legislatures -- it has no visibility into city councils, county commissions or school boards. We don't yet have a free, storable source for local measures; see the About page for why.

Summary

SB 1795 - This act requires the MO HealthNet program to cover biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a participant's disease or condition to guide treatment decisions when the test provides clinical utility to the patient as demonstrated by medical and scientific evidence, including, but not limited to labeled indications for a test approved by the U.S. Food and Drug Administration (FDA) or indicated tests for an FDA approved drug, Centers for Medicare and Medicaid Services national coverage determination or Medicare administrative contractor local coverage determinations, or nationally recognized clinical practice guidelines.

MO HealthNet managed care organizations contracted to deliver services to participants shall provide biomarker testing at the same scope, duration, and frequency as MO HealthNet otherwise provides to participants.

Health insurers, nonprofit health service plans, and health maintenance organizations issuing, amending, delivering, or renewing a health insurance contract on or after August 28, 2026, shall include coverage for biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a covered person's disease or condition to guide treatment decisions when the test provides clinical utility to the patient as demonstrated by medical and scientific evidence, including, but not limited to labeled indications for a test approved by the FDA or indicated tests for an FDA approved drug, centers for Medicare and Medicaid Services national coverage determination or Medicare administrative contractor local coverage determinations, or nationally recognized clinical practice guidelines. Such coverage shall be provided in a manner that shall limit disruptions in care, including the need for multiple biopsies or biospecimen samples.

The patient or prescribing practitioner shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy. Such process shall be readily accessible on the health insurer's, nonprofit health service plan's, or heath maintenance organization's website.

Nothing in this act shall be construed to require coverage of biomarker testing for screening purposes.
TAYLOR MIDDLETON

Official abstract, as published by the legislature.

  • SB 1795 is a bill in the Missouri Senate, 2026 session, introduced February 26, 2026.
  • Sponsored by Stephen Webber.
  • Current status: introduced.
  • Most recent action (May 7, 2026): Second Read and Referred S Families, Seniors and Health Committee.
  • Subjects: Commerce and Insurance, Department of, Health Care, Insurance - Health, Medicaid/MO Healthnet.

Contact your legislator about this bill

Bill text & documents

Sponsors

Primary: Stephen Webber

History

  1. Introduced, completed
  2. Passed Senate, in progress
  3. Passed House, not reached yet
  4. Sent to Governor, not reached yet
  5. Signed into law, not reached yet
  1. Senate S First Read
  2. Senate Second Read and Referred S Families, Seniors and Health Committee Latest

Source: Open States. Last checked November 5, 2026. How we keep this accurate ›